Pretransplant Cytomegalovirus-Specific Cellular Immunity and Risk of Viral Reactivation Following Lung Transplantation: A Prospective Cohort Study

J Infect Dis. 2021 Jul 15;224(2):312-317. doi: 10.1093/infdis/jiaa750.

Abstract

Cytomegalovirus (CMV) remains a significant burden in lung transplant recipients. Deficiencies in T-cell immunity posttransplant increase the risk of CMV-associated complications. However, it is not clear if underlying poor pretransplant immunity increases risk. To assess this, we recruited 39 prospective lung transplant patients and performed QuantiFERON-CMV on their peripheral blood. More than a third of prospective CMV-seropositive transplant recipients were CMV non-immune reactive (CMV-NIR) pretransplant. CMV-NIR status was associated with a significantly higher incidence of CMV reactivation posttransplant, demonstrating that dysfunctional CMV immunity in prospective lung transplant recipients is associated with an increased risk of viral reactivation posttransplant.

Keywords: T-cell immunity; cytomegalovirus; solid organ transplant; viral reactivation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cytomegalovirus Infections* / epidemiology
  • Cytomegalovirus Infections* / immunology
  • Humans
  • Immunity, Cellular*
  • Latent Infection / virology
  • Lung Transplantation* / adverse effects
  • Prospective Studies